From GlobeNewswire: 2025-04-16 12:36:00

Ipsen’s first-quarter 2025 sales grew by 11.6% at constant exchange rates, driven by all therapeutic areas. Regulatory submission to the EMA for tovorafenib for pediatric low-grade glioma and confirmation of annual financial goals for 2025 were also announced. The company’s CEO highlighted positive sales growth and progress in R&D.

Ipsen confirmed its financial targets for 2025, including total Group sales growth exceeding 5.0% at constant exchange rates and an operating margin above 30%. The company also announced key milestones for its R&D product portfolio in 2025, such as regulatory decisions for Cabometyx and Fidrisertib.

In the first quarter of 2025, Ipsen made progress with the regulatory acceptance of tovorafenib for examination in the EU and the initiation of Phase I for lPN01195, an RAF inhibitor. The company also successfully refinanced with a 500 million euro bond issuance, extending its debt maturity profile.

Ipsen will hold a conference call for investors and analysts today at 14:00 Paris time. The company plans to release its first-half results on July 31, 2025. All financial figures are in millions of euros and cover the first quarter of 2025, compared to the same period in 2024.



Read more at GlobeNewswire:: Ipsen enregistre une solide croissance de ses